Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia
oleh: Maria A. Pereda, Maria A. Pereda, Smitha Hosahalli Vasanna, Smitha Hosahalli Vasanna, Neha J. Desai, Neha J. Desai, Victoria Deng, Amma Owusu-Ansah, Amma Owusu-Ansah, Mari H. Dallas, Mari H. Dallas, Irina Pateva, Irina Pateva, Jignesh Dalal, Jignesh Dalal
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2022-11-01 |
Deskripsi
Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much of the published data for its use in pediatric blood disorders has been in post-transplant autoimmune cytopenias. Here we describe three patients in whom daratumumab was used outside of post-transplant autoimmune cytopenias, highlighting further potential uses of this medication.